SAPHTx: Injectable hydrogel for treating neovascular ocular diseases

Biplab Sarkar, Peter K. Nguyen, Zain Siddiqui, Vivek Kumar

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Technology: Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are leading causes of blindness in the world. Debilitating vision loss causes a significant socio-economic burden on afflicted geriatric, diabetic, at-risk youth, and under-represented populations. Proliferation of maladaptive blood vessels (angiogenesis) on the retina characterize these posterior segment neovascular diseases of the eye. Current treatments focus on inhibitors of angiogenesis (monoclonal antibodies or small molecule therapeutics). These treatments are expensive and require monthly intraocular dosing, resulting in patient discomfort and poor compliance. The proposed solution is a cost-effective, long lasting, and injectable hydrogel called SAPHTx (Figure 1). This hydrogel is composed exclusively of naturally occurring amino acids engineered to include an anti-angiogenic domain from the human plasminogen Kringle 5 (Kr5). We have further engineered the hydrogel to slowly dissociate over a 6-month period for long-term disease management. This will drastically reduce injection frequency, provide long-term attenuation of angiogenesis, improve patient compliance, and reduce the likelihood of side effects, such as endophthalmitis. Through interviews with advisors and key opinion leaders in ophthalmology, we have elected to pursue an initial target market of patients suffering from wet AMD. Depending on results of Phase II and Phase III trials, we will strategically expand to DR.

Original languageEnglish (US)
Title of host publicationSociety for Biomaterials Annual Meeting and Exposition 2019
Subtitle of host publicationThe Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting
PublisherSociety for Biomaterials
Number of pages1
ISBN (Electronic)9781510883901
StatePublished - Jan 1 2019
Event42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States
Duration: Apr 3 2019Apr 6 2019

Publication series

NameTransactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
Volume40

Conference

Conference42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
CountryUnited States
CitySeattle
Period4/3/194/6/19

All Science Journal Classification (ASJC) codes

  • Materials Chemistry
  • Biophysics
  • Biochemistry
  • Biotechnology
  • Biomaterials

Fingerprint Dive into the research topics of 'SAPHTx: Injectable hydrogel for treating neovascular ocular diseases'. Together they form a unique fingerprint.

  • Cite this

    Sarkar, B., Nguyen, P. K., Siddiqui, Z., & Kumar, V. (2019). SAPHTx: Injectable hydrogel for treating neovascular ocular diseases. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40). Society for Biomaterials.